In our experiment, let-7a inhibitor effectively reversed the effect of ANRIL siRNA on improving cisplatin-sensitivity, suggesting that silencing ANRIL may enhance the cisplatin-sensitivity of ovarian cancer cells by regulating the expression in its target gene let-7a. This evidence concerns the gene CDKN2B-AS1 and ovarian carcinoma.